CRAC — Q2 2026 Financial Report Analysis

Crown Reserve Acquisition Corp. I is not an operating business. It is a blank-check company (a SPAC): a shell that listed on Nasdaq in November 2025, raised $172.5 million from investors and parked it in a trust account while it looked for a private company to merge with. It has picked one, Carvix, Inc., a Miami-based buyer and operator of automotive-services businesses, in an all-stock deal announced on March 30, 2026 that values Carvix at $1.0 billion including earnout shares. For the quarter ended June 30, 2026 the shell reported net income of $1.35 million, all of it interest-like dividends on the trust's money-market holdings, and the deal itself had still not closed.

At a glance

• $176.5 million in trust, or about $10.23 per public share. That is roughly what a public shareholder can get back in cash by redeeming (handing back their shares) instead of taking stock in the merged company.
• $1.35 million net income, but none of it is "earnings" in the usual sense. Trust dividends of $1.55 million are added to the cash owed back to public shareholders, and the shell itself holds no cash at all.
• Deadline: February 10, 2027. If the Carvix merger has not closed by then, the company must wind up and return the trust money to public shareholders.

The quarter in numbers

A SPAC's income statement mostly shows how much the trust earned and what it cost to keep the shell running. There is no revenue: the 10-Q says the company has "neither engaged in any principal operations nor generated any revenues to date." The comparison with a year earlier is not meaningful because in Q2 2025 the company had just been formed (incorporated April 29, 2025) and had not yet gone public.

Operating margin is not shown: with no revenue it cannot be calculated. n/m = not meaningful.

The more useful comparison is with the previous quarter. In Q1 2026 the company reported a net loss of $263,493, because a $1.60 million loss on its warrants swamped $1.52 million of trust income. In Q2 the warrant loss was only $116,477, so trust income came through as a profit. For the six months to June 30, net income was $1,090,272.

Trust income: $1,548,367 on a trust that started the quarter at $174.9 million works out to roughly 3.5% a year, in line with short-term US Treasury yields at the time. The trust may only hold Treasuries maturing in 185 days or less, or money-market funds that invest only in them, so this line tracks short-term interest rates and nothing else.

Warrant loss: Each IPO unit came with half a warrant (a right to buy one share at $11.50 later on). Because a clause lets warrant holders receive cash in certain tender offers, the company has to carry the 8,625,000 public warrants as a liability at market value: $3.14 million at June 30, or about $0.36 per warrant, up from $1.42 million at December 31, 2025. When the warrants become more valuable, which tends to happen as a merger looks more likely, the shell books a loss. Most of the 2026 increase ($1.60 million) came in Q1, the quarter in which the Carvix agreement was signed.

What the headline numbers hide

• The profit does not belong to the shareholders it seems to. Every dollar of trust dividends ($3,073,108 in the first half) is added to the amount owed back to public shareholders if they redeem. Accounting calls this "accretion", and here it is charged straight against the company's equity. That is why the company made $1.09 million in the half-year and yet its shareholders' deficit widened, from -$1.37 million at December 31 to -$3.36 million at June 30.
• Zero cash outside the trust. The company "holds no operating cash." The sponsor (Crown Acquisition Sponsor LLC, the insiders who set up the SPAC) pays the bills on its behalf, out of private-placement money set aside for that purpose. That balance fell from $448,082 at December 31 to $210,670 at March 31 and $72,476 at June 30. Operating cash flow for the half-year was -$375,606, against reported net income of +$1.09 million, the gap being trust dividends that never leave the trust.
• Going-concern warning. Management states there is "substantial doubt" about the company's ability to continue as a going concern, because it must liquidate if no merger closes by the deadline. This is standard language for a SPAC with a hard deadline, not a sign of trouble in an operating business. It still matters: the deal has to close for the shell to survive.
• Warrant valuation is an estimate. No price exists for the warrant liability itself. It is modelled using the implied volatility (how much the market expects prices to swing) of just two peer SPACs' warrants at June 30. The filing says a 1-point change in that assumption moves the liability by about $240,000, which is three times the quarter's operating costs.
• Costs are small. Operating costs were $78,125 in the quarter and $261,962 for the half-year. The real costs of the Carvix deal (legal, accounting, advisers) are "expected to be paid at or following the Closing from the funds released from the Trust Account", so they are not in these numbers yet.

The Carvix deal: what is agreed

Most of what moves this stock is the merger, so here are its terms as filed:

• Structure: Crown Reserve moves its legal home from the Cayman Islands to Delaware, then a subsidiary merges into Carvix. Carvix's management runs the combined company, and Carvix nominates four of the five directors.
• Price: Carvix's owners receive 50,000,001 new shares at closing. At the deal's $10.00 reference price that is $500 million. They can earn up to 50,000,100 more shares over 2027-2030 if Carvix hits revenue and EBITDA targets (EBITDA is a rough measure of operating cash profit). The $1.0 billion headline value counts those earnout shares, so half of it depends on future performance. The sponsor can earn up to 3,000,000 extra shares on the same milestones.
• The targets tell you the size of business being promised. The year-one (2027) earnout targets are $276.8 million of revenue and $10.38 million of EBITDA, an EBITDA margin of about 3.75%. They rise to $436.88 million and $21.84 million by years three and four. Carvix's actual historical financials have not yet been published in any SEC filing, so there is no way to check today how far it is from those targets.
• Financing: The SPAC agreed to use "reasonable best efforts" to raise at least $80 million from a PIPE (a private sale of new shares to selected investors at closing) plus a $20 million equity credit line. The deal only needs $10 million of cash at closing after redemptions and expenses. In practice it could close even if nearly every public shareholder takes their ~$10.23 back. None of the 8-Ks filed through September 28, 2026 announces a signed PIPE.
• Dilution for public holders: 17,250,000 public shares (plus 3,450,000 more from the rights that came with the units, at 0.20 shares per right) set against 50 million shares for Carvix's owners, before any earnout. Even with no redemptions, today's public shareholders would end up a minority owner of Carvix. The sponsor paid $25,000 for its 4,312,500 founder shares, about $0.006 each, which is why insiders can come out ahead even if the stock later trades below $10.

What has happened since June 30

• August 26, 2026: a first amendment rewrote the description of the shareholder votes to match the SPAC's articles. Under those articles, only Class B (founder) shareholders vote on the move to Delaware, the new charter and the election of directors. Class A public holders vote on the merger itself. The amendment also set minimum salaries for named Carvix executives.
• September 23, 2026: a second amendment pushed the date after which either side can walk away from September 30, 2026 to the later of February 10, 2027 and the SPAC's own deadline. The original date was about to pass, which shows the timetable has slipped.
• No Form S-4 appears on EDGAR yet for this company. The S-4 is the registration and proxy document that has to be declared effective before shareholders can vote, and it is where Carvix's audited financials will first be made public. Until it is filed, investors are judging a $1.0 billion headline valuation with no published Carvix numbers.

Takeaway: CRAC is a $176.5 million pot of Treasury-backed cash, about $10.23 per share, attached to an option on a merger with Carvix. Its quarterly "profit" is just trust interest that is owed back to redeeming shareholders. The real question is whether the Carvix deal closes by February 10, 2027 and what Carvix's first published financials show against an earnout plan built on $276.8 million of 2027 revenue.

What to watch next

• The S-4 filing. It is the gating item for a shareholder vote and the first look at Carvix's revenue, EBITDA and debt. With roughly four months left to the February 10, 2027 deadline and no S-4 on file in mid-October, timing is tight. SEC review of an S-4 typically takes months, so another extension (which would need a shareholder vote) or a slip past the deadline is a real possibility.
• Whether a PIPE is signed. An $80 million commitment would show that outside investors accept the valuation. Without one, and with a $10 million minimum cash condition, the combined company could start public life with little cash if redemptions are high.
• Redemption levels at the vote. For a public holder, the trade-off is the ~$10.23 per share in trust against shares in Carvix.
• Next filing: the Q3 2026 10-Q, due by mid-November 2026, should show the trust at roughly $178 million if money-market yields hold. It may also update the deal status.

Our view: the shell's own finances are uneventful and will stay that way until closing. Its trust yield moves with short-term Treasury rates, and its costs are small and paid by the sponsor. Everything that matters for the share price sits in a filing that has not been made yet.